These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23931807

  • 1. Fabry disease.
    Toyooka K.
    Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
    [Abstract] [Full Text] [Related]

  • 2. Fabry disease.
    Toyooka K.
    Curr Opin Neurol; 2011 Oct; 24(5):463-8. PubMed ID: 21825987
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
    Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO.
    Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
    [Abstract] [Full Text] [Related]

  • 4. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
    Schiffmann R.
    Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
    [Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.
    Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M.
    Neurology; 2004 Apr 13; 62(7):1066-72. PubMed ID: 15079003
    [Abstract] [Full Text] [Related]

  • 6. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC.
    Neurobiol Dis; 2009 Jan 13; 33(1):48-56. PubMed ID: 18848893
    [Abstract] [Full Text] [Related]

  • 7. Neurological complications in Fabry disease.
    Dütsch M, Hilz MJ.
    Rev Med Interne; 2010 Dec 13; 31 Suppl 2():S243-50. PubMed ID: 21211673
    [Abstract] [Full Text] [Related]

  • 8. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R, Rodrigues D, Assunção M, Macedo MF, Azevedo O, Cunha D, Oliveira P, Sá Miranda MC.
    Gene; 2014 Feb 15; 536(1):97-104. PubMed ID: 24334116
    [Abstract] [Full Text] [Related]

  • 9. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
    Üçeyler N, He L, Schönfeld D, Kahn AK, Reiners K, Hilz MJ, Breunig F, Sommer C.
    J Peripher Nerv Syst; 2011 Dec 15; 16(4):304-14. PubMed ID: 22176145
    [Abstract] [Full Text] [Related]

  • 10. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF, Quinta R, Pereira CS, Sa Miranda MC.
    Mol Genet Metab; 2012 May 15; 106(1):83-91. PubMed ID: 22425450
    [Abstract] [Full Text] [Related]

  • 11. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH.
    Hum Gene Ther; 1999 Jul 01; 10(10):1667-82. PubMed ID: 10428212
    [Abstract] [Full Text] [Related]

  • 12. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS.
    J Gene Med; 2004 Jan 01; 6(1):85-92. PubMed ID: 14716680
    [Abstract] [Full Text] [Related]

  • 13. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A, Lanfranconi S, Valcarenghi C, Bresolin N, Micieli G, Baron P.
    Acta Neurol Scand; 2012 Aug 01; 126(2):77-97. PubMed ID: 22428782
    [Abstract] [Full Text] [Related]

  • 14. Fabry disease.
    Tarabuso AL.
    Skinmed; 2011 Aug 01; 9(3):173-7. PubMed ID: 21675497
    [Abstract] [Full Text] [Related]

  • 15. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R, Olea T.
    Nefrologia; 2002 Aug 01; 22(6):540-6. PubMed ID: 12516287
    [Abstract] [Full Text] [Related]

  • 16. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A, Muşat A, Doscan A, Bari M, Zapucioiu C, Urdea E, Cochior D, Peţa D.
    Rom J Intern Med; 2006 Aug 01; 44(2):201-10. PubMed ID: 17236300
    [Abstract] [Full Text] [Related]

  • 17. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F, Wanner C.
    J Nephrol; 2008 Aug 01; 21(1):32-7. PubMed ID: 18264934
    [Abstract] [Full Text] [Related]

  • 18. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T, Murray GJ, Qin G, Quirk JM, Ohshima T, Qasba P, Clark K, Kulkarni AB, Brady RO, Medin JA.
    Proc Natl Acad Sci U S A; 2000 Jun 20; 97(13):7515-20. PubMed ID: 10840053
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.